CHAPEL HILL, N.C., Aug. 27 Pharmaceutical companies areincreasingly turning to e-journals and other alternative media to speed up thetraditionally time-consuming scientific publication process, according to areport released by Best Practices, LLC.
Fully 50 percent of companies participating in a recent benchmarking studyindicated that they are becoming more focused on non-traditional media inorder to expand and accelerate publication of clinical trial results. Thestudy included such influential companies as Pfizer, GlaxoSmithKline, EliLilly and Merck.
Using new publication outlets, in addition to such standards as theJournal of the American Medical Association, is only one of the ways thatpharmas are responding to a demand for faster and more transparent scientificpublications. The study also found that companies are posting trial resultson designated industry or government websites, for example.
To receive a complimentary summary of the full report "ScientificPublications Strategy: Managing Reputation, Clinical Trial Results andCommercial Relevance," click on http://www3.best-in-class.com/rr844.htm . Thestudy guides pharmaceutical and biotechnology companies in the transition tothe new publishing environment.
"Developing a world-class publications organization is more challengingthan ever given the heightened regulatory environment and the need for greatertransparency," said Best Practices CEO Chris Bogan. "Our research found thatleading companies are adopting new strategies to help them maintain scientificcredibility within top-tiered journals while producing commercially relevantinformation to achieve brand success."
For more information on this report, contact Cameron Tew email@example.com or (919) 767-9246. To download a copy of the reportsummary, go to http://www3.best-in-class.com/rr844.htm .
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profoundprinciple that organizations can chart a course to superior economicperformance by studying the best business practices, operating tactics andwinning strategies of world-class companies. For more than 15 years, ourhighly credentialed research staff has conducted primary research exclusivelyfor our Fortune 500 client base.Key topic areas in the research include: * Transition of global publication function from commercial to clinical oversight * Tactics for handling publication of neutral or negative clinical trial results * Optimal structure for the global publications function * Strategy changes for the new marketplace Among the key topics included in this report are: * Centralization of publications strategy, planning and delivery * Trends surrounding regional strategy contribution * Strategies for publishing neutral/negative results * Outsourcing of global publications resources * Measures used for performance evaluation
SOURCE Best Practices, LLC